202 related articles for article (PubMed ID: 35859710)
1. Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
Megna M; Potestio L; Fabbrocini G; Ruggiero A
Psoriasis (Auckl); 2022; 12():205-212. PubMed ID: 35859710
[TBL] [Abstract][Full Text] [Related]
2. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
[TBL] [Abstract][Full Text] [Related]
3. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Ruggiero A; Fabbrocini G; Cinelli E; Megna M
Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
[TBL] [Abstract][Full Text] [Related]
4. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
5. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
[TBL] [Abstract][Full Text] [Related]
6. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
[TBL] [Abstract][Full Text] [Related]
7. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
8. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.
Megna M; Fabbrocini G; Cinelli E; Camela E; Ruggiero A
J Dermatolog Treat; 2022 Mar; 33(2):1074-1078. PubMed ID: 32705907
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
[TBL] [Abstract][Full Text] [Related]
13. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
Puig L
Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis.
Zheng J; Chen W; Yi X; Yu N; Ding Y; Gao Y
Front Med (Lausanne); 2023; 10():1285972. PubMed ID: 38162889
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
16. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
[TBL] [Abstract][Full Text] [Related]
17. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.
Ruggiero A; Fabbrocicni G; Cacciapuoti S; Potestio L; Gallo L; Megna M
Clin Cosmet Investig Dermatol; 2023; 16():529-536. PubMed ID: 36873660
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
J Dermatolog Treat; 2022 Aug; 33(5):2560-2564. PubMed ID: 35098859
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Nakamura M; Lee K; Jeon C; Sekhon S; Afifi L; Yan D; Lee K; Bhutani T
Dermatol Ther (Heidelb); 2017 Sep; 7(3):281-292. PubMed ID: 28639011
[TBL] [Abstract][Full Text] [Related]
20. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.
Michelucci A; Manzo Margiotta F; Panduri S; Tonini A; Romanelli M; Morganti R; Janowska A; Dini V
Dermatol Ther; 2022 Apr; 35(4):e15339. PubMed ID: 35088508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
